Orally administered ranitidine plasma concentrations before and after biliopancreatic diversion in morbidly obese patients

Maria Laura Cossu, Silvio Caccia, Massimiliano Coppola, Enrico Fais, Matteo Ruggiu, Claudia Fracasso, Angelo Nacca, Giuseppe Noya

Research output: Contribution to journalArticle

Abstract

Background: Patients undergoing biliopancreatic diversion (BPD) may develop gastric ulcers, particularly within the first postoperative year. The prophylactic use of antisecretory compounds at the usual therapeutic doses, mainly conventional H2-receptor antagonists such as ranitidine, may reduce the incidence of this complication, which occurs in ~ 5% of patients after BPD. Methods: The authors measured the plasma concentrations of ranitidine (300 mg orally) in obese patients, before and 8 months after BPD, and in control subjects of normal weight. The study included 11 obese patients undergoing BPD (age 45 ± 14 years; preoperative and postoperative weights 124 ± 21 and 92 ± 11 kg) and 10 normal-weight subjects (age 37 ± 13 years, weight 67 ± 9 kg). Results: Postoperative ranitidine plasma concentrations showed only minor differences from preoperative levels, with slightly higher maximum concentrations occurring sooner. The mean area under the curve was on the average 30% higher than preoperatively. All parameters, however, were similar to those in control subjects. Conclusions: BPD per se does not greatly affect the pharmacokinetic behavior of ranitidine, and therefore a conventional dosage regimen appears adequate for the prophylaxis and therapy of gastric ulcers associated with this operation.

Original languageEnglish
Pages (from-to)36-39
Number of pages4
JournalObesity Surgery
Volume9
Issue number1
Publication statusPublished - 1999

Keywords

  • Biliopancreatic diversion
  • Morbid obesity
  • Ranitidine plasma concentrations

ASJC Scopus subject areas

  • Surgery

Fingerprint Dive into the research topics of 'Orally administered ranitidine plasma concentrations before and after biliopancreatic diversion in morbidly obese patients'. Together they form a unique fingerprint.

  • Cite this

    Cossu, M. L., Caccia, S., Coppola, M., Fais, E., Ruggiu, M., Fracasso, C., Nacca, A., & Noya, G. (1999). Orally administered ranitidine plasma concentrations before and after biliopancreatic diversion in morbidly obese patients. Obesity Surgery, 9(1), 36-39.